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Insulin-like growth factor 1 and risk of depression in older
people: the English Longitudinal Study of Ageing
S Chigogora1, P Zaninotto1, M Kivimaki1, A Steptoe1 and GD Batty1,2
Depressive disorders are a leading cause of disability in older age. Although the role of psychosocial and behavioural predictors has
been well examined, little is known about the biological origins of depression. Findings from animal studies have implicated insulin-
like growth factor 1 (IGF-1) in the aetiology of this disorder. A total of 6017 older adults (mean age of 65.7 years; 55% women) from
the English Longitudinal Study of Ageing provided serum levels of IGF-1 (mean= 15.9 nmol l− 1, s.d. 5.7) during a nurse visit in 2008.
Depression symptoms were assessed in the same year and again in 2012 using the eight-item Center for Epidemiologic Studies
Depression Scale. Self-reports of a physician-diagnosis of depression were also collected at both time points. In separate analyses
for men and women, the results from both the cross-sectional and longitudinal analyses revealed a ‘U’-shaped pattern of
association, such that lower and higher levels of IGF-1 were associated with a slightly elevated risk of depression, whereas the
lowest risk was seen around the median levels. Thus, in men, with the lowest quintile of IGF-1 as the referent, the age-adjusted odds
ratios (95% conﬁdence interval) of developing depression symptoms after 4 years of follow-up, for increasing quintiles of IGF-1,
were: 0.51 (0.28–0.91), 0.50 (0.27–0.92), 0.63 (0.35–1.15) and 0.63 (0.35–1.13) (P-value for quadratic association 0.002). Some
attenuation of these effects was apparent after adjustment for co-morbidity, socioeconomic status and health behaviours. In
conclusion, in the present study of older adults, there was some evidence that moderate levels of IGF-1 levels conferred a reduced
risk of depression.
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INTRODUCTION
Depression, a major public health problem, has profound effects on
the economy and on individuals. According to the World Health
Organization, it is the leading cause of disability worldwide,1
responsible for 65 million disability-adjusted life years in 2008.2 In
addition to being an important disease in its own right, depression is
also associated with an increased risk of suicide,3,4 cardiovascular
disease,5–7 some cancers8 and premature mortality.9–11 Although
effective treatments for depression are available, the majority of
cases among older people remain undiagnosed; prevention of the
disorder is therefore crucial.12,13 A series of studies have identiﬁed a
range of behavioural (heavy alcohol use, some dietary character-
istics) and social (loneliness, socioeconomic disadvantage, bereave-
ment) predictors of depression in later life.14,15 Although the
aetiological role of weight, height, genetic factors and several
plasma markers has been examined,16–18 relatively less attention has
been paid to biological risk factors.
Insulin-like growth factor 1 (IGF-1) is a complex peptide
hormone produced in multiple tissue sites whose main function
is to mediate cell growth, differentiation and transformation by
promoting mitosis and inhibiting apoptosis.19 Evidence from
laboratory studies suggests that expression and function of
IGF-1 is similar in humans and rodents.20,21 In humans, elevated
IGF-1 levels are associated with increased skeletal muscle and
tissue growth,22,23 bone mineral density,24 risk of selected
malignancies25 and cardiovascular disease.26,27 IGF-1 has also
been implicated in psychological functioning of both animals and
humans. Thus, rodents whose circulating IGF-1 levels were
experimentally perturbed displayed marked changes in mood.
For instance, the application of a viral vector to drastically reduce
circulating IGF-1 levels resulted in mice showing signs of
depression as assessed using the forced swim and tail suspension
tests.28 Elsewhere, rodents given IGF-1 infusions experienced a
reduction in depression symptoms relative to a no treatment
group.29,30 In laboratory-based experimental studies of humans,
through a range of mechanisms such as altered neuroprotection,
modulation of neuronal excitability, brain angiogenesis, hippo-
campal neurogenesis and neuroplasticity,31–33 alterations of IGF-1
levels have been linked to hippocampal dysfunction, which in turn
have been associated with mood disorders.34,35 IGF-1 expression
in the hippocampus has also been found to be reduced in
sufferers of depression, and enhanced by the administration of
antidepressants.36
Of the two general population-based studies of which we are
aware, one showed that low IGF-1 in women, but high levels in
men, were predictive of depressive disorder.37 In another, relative
to moderate levels, women with high IGF-1 values experienced an
elevated risk of minor depression.38 In both the studies, incident
depression was rare resulting in low statistical power, and in
one,38 the measurement of depression was made using a non-
standard scale of unknown validity. Accordingly, against this
background of study paucity, discordant ﬁndings and methodo-
logical concerns, we examined the cross-sectional and long-
itudinal association between IGF-1 and depression symptoms in a
large, well-established general population-based study of older
adults in England (UK).
1Department of Epidemiology and Public Health, University College London, London, UK and 2Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh,
Edinburgh, UK. Correspondence: S Chigogora, Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London WC1E 6BT, UK.
E-mail: s.chigogora.11@ucl.ac.uk
Received 1 June 2016; accepted 18 July 2016




The English Longitudinal Study of Ageing is an ongoing prospective cohort
study of adults aged 50 years and over who, when recruited, lived in
private households in the United Kingdom. Initiated in 2002/3, the original
sample was drawn from participants in the Health Surveys for England, a
collection of population-based cross-sectional studies. With data collection
occurring every 2 years, as of 2012, there have been a total of six waves. As
IGF-1 levels were ﬁrst measured in 2008 (wave 4), this represents our study
‘baseline’ for the purposes of the present analyses. Ethical approval for all
data collection was granted by the National Research and Ethics
Committee,39 and the participants provided written consent.
Measurement of IGF-1
Study members were requested not to eat, smoke, drink alcohol or engage
in vigorous exercise for 30 min before blood being drawn. The whole-
blood samples were transported to a single laboratory (Royal Victoria
Inﬁrmary, Newcastle, UK), where the serum was separated, frozen at 40 °C
and batch-assayed (completed in 2008) using the DPC Immulite 2000
method. The inter-assay coefﬁcient of variation for IGF-1 across a range of
levels was ⩽ 3.7%, and the intra-assay coefﬁcient of variation was ⩽ 5.3%.
The IGF-1 values are reported as whole numbers (range: 3–200 nmol l− 1).40
Depressive symptoms and physician-diagnosis of depression
Depression symptoms were ascertained during a computer-assisted
personal interview using the eight-item Center for Epidemiologic Studies
Depressive (CES-D8) scale.41 Each item requires a dichotomous (yes/no)
response, and scores range between 0 and 8 (higher score denotes more
severe symptoms). Consistent with other analyses, we deﬁned ‘caseness’ as
anyone scoring 4 or above.42 The CES-D has been widely used in
population-based studies of older groups43,44 and has been validated
against clinician-assessed depression.45 Notably, the shortened CES-D8 has
good internal consistency (Cronbach’s α=0.78) and similar psychometric
properties to the full 20-item CES-D.46 The participants also had an
opportunity to self-report a physician-diagnosis of depression. During the
main English Longitudinal Study of Ageing interview, the participants ﬁrst
reported whether they had ever been diagnosed with any emotional,
nervous or psychiatric problems. This was followed by the identiﬁcation of
the actual condition as selected from a list of ailments common to this
group, of which depression was one.47 The assessment of depression in
this manner has been shown to be valid in a separate study using the
Structured Clinical Interview for DSM-IV Axis I Disorders as the gold
standard.48 Both these measurements of depression were made in 2008
and 2012.
Measurement of covariates
We grouped covariates, including potential confounders and mediators,
according to theme. Anthropometric measures comprised height and
weight, which were measured during the nurse visit; body mass index (kg/
m2) calculated by dividing each individual’s measured weight by height
squared. Psychosocial factors were level of education (no qualiﬁcation,
completed secondary (high school) education, educated beyond second-
ary education but below degree level, and educated beyond degree level);
quintiles of net non-pension wealth (derived from an estimation of
ﬁnancial wealth and physical assets reported by study participants and
their partners, excluding pension savings and net of debts such as credit
cards and loans);49 and marital status (currently living with a partner or
not). Health-related behaviours comprised smoking status (current, ex-
smoker and never), frequency of alcohol consumption in the past year (less
than daily/daily, with consumption on at least 5 days of the week being
classed as daily consumption) and leisure time physical activity (low/
sedentary, moderate or high activity of exercises such as jogging, cycling,
gardening, walking). Co-morbidities were self-reported physician-diagnosis
of cancer, diabetes or cardiovascular disease (heart murmur, ischaemic
heart disease, abnormal heart rhythm, stroke, valvular heart disease or any
other reported heart disease).
Statistical analysis
In Figure 1, we illustrate the ﬂow of participants through the study. Of the
8218 participants at baseline in 2008 who had received a nurse visit, we
excluded those who had missing values for IGF-1 (N=2158) comprising
people who declined to give blood (771), unsuitability or loss of a blood
sample (395), or failure to obtain blood sample (992). We also excluded
participants with missing values for depression symptoms (43), although
none had missing data for physician-diagnosed depression at baseline. The
cross-sectional sample therefore comprised 6017 study members from
data collection in 2008. We also carried out the longitudinal analyses, again
using IGF-1 values from 2008 but relating to new (incident) cases of
depression at resurvey in 2012. In deriving new cases of depression, we
excluded participants who were classed as depression cases in 2008,
resulting in samples of 4419 for the analysis of depression symptoms and
4768 for physician-diagnosed depression.
Multivariable logistic regression analyses were used to summarize the
association of IGF-1 levels with both depression outcomes. The lowest
quintile of IGF-1 was used as the referent. There is existing evidence of
differential IGF-1-depression relationships in men and women,39,40,50 so we
present gender-speciﬁc analyses here also. We adjusted effect estimates
for known covariates in a stepwise manner. In our analyses, depression
symptoms were our primary outcome, with physician-diagnosed depres-
sion used to test convergence of evidence. All the analyses were carried
out using Stata12SE software.51
RESULTS
IGF-1 and baseline characteristics: cross-sectional analyses
In Table 1 (women) and Table 2 (men), we present baseline study
participant characteristics according to IGF-1 quintiles. As
expected, mean IGF-1 values were higher in men (16.5 nmol l− 1)
than women (15.2 nmol l− 1). In men and women, IGF-1 was
inversely associated with age and directly related to height and
Figure 1. Derivation of the analytical sample for cross-sectional
(2008) and longitudinal (2012) analyses of the association between
serum IGF-1 and depression: the English Longitudinal Study of
Ageing. CES-D, Center for Epidemiologic Studies Depressive scale;
IGF-1, insulin-like growth factor 1.
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socioeconomic position. Psychosocial factors, which included
social position and cohabiting with a partner, typically occurred
at more favourable levels in men and women with higher
IGF-1 values. A total of 776 participants (12.9%) had CES-D8
scores of 4 and above at baseline and were therefore denoted as
‘cases’ (71.8% were female); 344 (5.7%) participants reported
physician-diagnosis of depression. As for some of the somatic
conditions such as cancer, there was a suggestion that
the greatest proportions of both men and women who reported
high depression symptoms and self-declared physician-diagnosed
depression were seen in the lowest and highest quintiles
of IGF-1, although the differences across groups were not
considerable.
IGF-1 and depression: cross-sectional analyses
In Table 3, the computation of odds ratios for the cross-sectional
association between IGF-1 and depression symptoms supports
earlier evidence of a somewhat higher risk of depression
symptoms at opposite ends of the IGF-1 continuum in men and
women in this study. Although a similar 'U’-shaped pattern was
apparent for physician-diagnosed depression (see Supplementary
Table 1), statistical signiﬁcance at conventional levels was rarely
apparent for individual point estimates in these analyses.
Adjustment for an array of covariates had little impact on this
pattern of association, although taking into account all covariates
simultaneously led to some ﬂattening of the IGF-1–depression
relationship.
IGF-1 and depression: prospective analyses
In Table 4, we depict the association between IGF-1 and
depression symptoms after 4 years of follow-up in participants
initially free of depression symptoms at baseline (longitudinal
analyses). A ‘U’-shaped pattern of risk was again observed for the
IGF-1–depression association in both genders based on sympto-
matology. Similar results were apparent for physician-diagnosis of
depression but only among women (Supplementary Table 2).
Statistical signiﬁcance was, again, rarely apparent for individual
point estimates. In none of our analyses was there strong
statistical evidence that gender modiﬁed the IGF-1–depression
association (P-values for interaction for the multiply adjusted odds
of developing depression symptoms and physician-diagnosed
depression in longitudinal analyses are 0.531 and 0.275,
respectively).
DISCUSSION
The main ﬁnding of this study of older people was that having
IGF-1 levels at opposing ends of the continuum was associated
with a slightly higher risk of depression symptoms. Similar results
were apparent for physician-diagnosis of depression.
Comparison with existing studies
Our results partially accord with the two population studies on
IGF-1 and depression of which we are aware. When compared
with data from the Study of Health in Pomerania in Germany,38
Table 1. Baseline characteristics of study participants according to quintiles of serum IGF-1 (nmol l− 1): 3311 women in the English Longitudinal
Study of Ageing, 2008
IGF-1 quintile (range) P-value for
difference
1 2 3 4 5 All
(2–11 nmol l− 1) (12–14 nmol l− 1) (15–16 nmol l− 1) (17–20 nmol l− 1) (21–65 nmol l− 1)
Subject numbers 861 813 479 681 477
IGF-1, nmol l− 1, mean (s.e.) 9.2 (0.06) 13.0 (0.03) 15.5 (0.02) 18.3 (0.04) 25.2 (0.22) 15.2 (0.10) o0.001
Age, years, mean (s.e.) 68.7 (0.4) 66.2 (0.3) 65.1 (0.4) 64.4 (0.3) 63.2 (0.4) 65.9 (0.2) o0.001
Anthropometry mean (s.e.)
Height, cm 158.8 (0.3) 159.9 (0.2) 160.4 (0.3) 160.6 (0.2) 160.9 (0.3) 160.0 (0.1) o0.001
BMI, kg/m2 28.7 (0.2) 28.4 (0.2) 27.6 (0.2) 27.7 (0.2) 27.6 (0.2) 28.1 (0.1) o0.001
Co-morbidities, % (s.e.)
Diabetes 8.5 (0.9) 6.0 (0.8) 6.9 (1.2) 5.9 (0.9) 7.8 (1.2) 7.0 (0.4) 0.213
Cancer 6.6 (0.8) 4.5 (0.7) 4.6 (1.0) 3.2 (0.7) 6.1 (1.1) 5.0 (0.4) 0.029
Cardiovascular disease 26.6 (1.5) 24.4 (1.5) 21.5 (1.9) 18.6 (1.5) 23.9 (2.0) 23.3 (0.7) 0.005
Psychosocial factors, % (s.e.)
Lowest wealth quintile 23.1 (1.4) 16.0 (1.3) 11.7 (1.5) 15.0 (1.4) 14.5 (1.6) 16.8 (0.7) o0.001
No educational
qualiﬁcations
34.1 (1.6) 30.3 (1.6) 29.0 (2.1) 27.2 (1.7) 23.1 (1.9) 29.4 (0.8) 0.001
Lives alone 43.1 (1.7) 37.5 (1.7) 28.4 (2.1) 32.8 (1.8) 36.3 (2.2) 36.5 (0.8) o0.001
Behavioural factors, % (s.e.)
Sedentary or low physical
activity
39.4 (1.7) 30.0 (1.6) 26.5 (2.0) 25.8 (1.7) 30.2 (2.1) 31.1 (0.8) o0.001
Current smoking 12.2 (1.1) 13.3 (1.2) 12.7 (1.5) 13.5 (1.3) 16.1 (1.7) 13.4 (0.6) 0.663
Daily alcohol intake 15.2 (1.2) 16.0 (1.3) 16.5 (1.7) 15.9 (1.4) 16.8 (1.7) 16.0 (0.6) 0.902
Depression
CES-D score, mean (s.e.) 1.8 (0.07) 1.6 (0.07) 1.3 (0.08) 1.5 (0.07) 1.6 (0.09) 1.6 (0.03) o0.001
High depression symptoms,
% (s.e.)
20.6 (1.3) 15.9 (1.3) 14.4 (1.6) 14.2 (1.3) 17.8 (1.5) 16.8 (0.7) 0.005
Physician-diagnosed
depression, % (s.e.)
7.1 (0.9) 6.4 (0.9) 5.4 (1.0) 6.5 (0.9) 6.7 (1.1) 6.5 (0.4) 0.837
Abbreviations: BMI, body mass index; CES-D, Center for Epidemiologic Studies Depressive scale; IGF-1, insulin-like growth factor 1.
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our results were in agreement with the ﬁnding that having a low
IGF-1 level was associated with higher risk of developing
depression symptoms among women. However, we also found a
similar association for men. Our results are also in agreement with
the second existent study, which used data from The Longitudinal
Aging Study Amsterdam,39 where associations were found
between median levels of IGF-1 and lower risk of both prevalent
and incident depression symptoms. Once again, the main
difference with this present study is that we identiﬁed this
association among both men and women. The ‘U’-shaped
relationship that we identiﬁed between IGF-1 and depression
symptoms is supported by observations of increased reports of
lifetime affective disorders in individuals with lower (pituitary
dwarﬁsm) and higher (acromegaly) levels of this growth
hormone.52–54 It may be that this apparent differential result for
men and women in these existing studies is due to statistical
instability.
To directly compare our ﬁndings with some of those already
published, we re-categorized IGF-1 levels in our own analyses. In
these new analyses, we still found evidence for increased odds of
depression symptoms among those with very low and very high
IGF-1. Our results after initial re-categorization of IGF-1 levels38
showed that, after 4 years of follow-up, the age-adjusted odds
ratios (95% conﬁdence interval) of depression symptoms for the
lowest and highest tenth percentiles of IGF-1 among men were
2.26 (1.25, 4.09) and 1.51 (0.86, 2.68), respectively when compared
with those with intermediate levels; whereas the corresponding
results in women were 1.38 (0.93, 2.07) and 1.27 (0.77, 2.10).
Following further re-categorization,39 when compared with the
middle tertile, the odds ratios (95% conﬁdence interval) of
depression for the lowest and highest tertiles of IGF-1 among
men were 1.14 (0.72, 1.80) and 0.89 (0.55, 1.43), respectively, and
corresponding results for women were 1.08 (0.79, 1.49) and 1.14
(0.79, 1.65).
Our ﬁndings, however, contrast with the results from the
handful of case–control studies where IGF-1 levels were found to
be elevated in depressed patients compared with healthy
controls.55,56 This may be owing to speciﬁc consequences of
previous use of anti-depressant medications, such as where they
have been seen to improve expression of IGF-1 and other
neutrophic and growth factors in the hippocampus.31 Further-
more, there may yet be other unknown biological mechanisms
related to the state of being depressed, which cause serum IGF-1
levels to increase, implying reverse causation in the reported
case–control studies, where the depression in the cases had, in
fact, caused the IGF-1 levels to increase. In this study, we
attempted to circumvent the problem of reverse causality by
utilizing depression incidence as our outcome in the longitudinal
analyses; that is, new cases of depression in participants who, at
baseline, were symptom-free and had not previously reported
being diagnosed with the condition by a physician.
Table 2. Baseline characteristics of study participants according to quintiles of serum IGF-1 (nmol l− 1): 2706 men in the English Longitudinal Study of
Ageing, 2008
IGF-1 quintile (range) P-value for
difference
1 2 3 4 5 All
(2–11 nmol l− 1) (12–14 nmol l− 1) (15–16 nmol l− 1) (17–20 nmol l− 1) (21–65 nmol l− 1)
Subject number 483 615 384 667 557
IGF-I, nmol l− 1 (s.e.) 9.3 (0.08) 13.1 (0.03) 15.5 (0.03) 18.4 (0.04) 25.1 (0.22) 16.5 (0.11) o0.001
Age, years, mean (s.e.) 68.7 (0.5) 65.3 (0.4) 65.0 (0.5) 64.4 (0.3) 64.0 (0.3) 65.4 (0.2) o0.001
Anthropometry, mean (s.e.)
Height, cm 171.7 (0.3) 172.8(0.3) 173.8 (0.4) 173.8 (0.3) 174.2 (0.3) 173.3 (0.1) o0.001
BMI, kg/m2 28.6 (0.2) 27.8 (0.2) 27.9 (0.2) 28.0 (0.2) 27.9 (0.2) 28.0 (0.1) 0.078
Co-morbidities, % (s.e.)
Diabetes 12.6 (1.5) 6.8 (1.0) 6.3 (1.2) 10.6 (1.2) 11.1 (1.3) 9.6 (5.7) 0.001
Cancer 4.8 (1.0) 5.4 (1.0) 4.4 (1.1) 5.2 (0.9) 4.3 (0.9) 4.9 (4.1) 0.897
Cardiovascular disease 31.5 (2.1) 24.6 (1.7) 25.7 (2.2) 26.3 (1.7) 27.2 (1.9) 26.9 (0.9) 0.121
Psychosocial factors, % (s.e.)
Lowest wealth quintile 18.0 (1.8) 13.3 (1.4) 14.3 (1.8) 12.0 (1.3) 13.1 (1.4) 13.9 (0.7) 0.167
No educational
qualiﬁcations
25.9 (2.0) 20.0 (1.6) 23.4 (2.1) 17.3 (1.5) 16.3 (1.6) 20.1 (0.8) 0.056
Lives alone 26.7 (2.0) 20.7 (1.6) 20.8 (2.1) 21.4 (1.6) 16.7 (1.6) 21.1 (0.8) 0.003
Behavioural factors, % (s.e.)
Sedentary or low physical
activity
26.9 (2.0) 18.4 (1.6) 22.1 (2.1) 17.4 (1.5) 21.9 (1.8) 20.9 (0.8) 0.005
Current smoking 13.7 (1.6) 12.7 (1.3) 12.8 (1.7) 11.8 (1.3) 14.0 (1.5) 12.9 (0.6) 0.306
Daily alcohol intake 28.6 (2.2) 24.7 (1.7) 27.6 (2.2) 26.4 (1.7) 24.1 (1.8) 26.1 (0.8) o0.001
Depression
CES-D8 score, mean (s.e.) 1.0 (0.08) 0.9 (0.06) 0.8 (0.07) 0.9 (0.06) 1.1 (0.07) 0.9 (0.03) 0.07
High depression symptoms,
% (s.e.)
9.3 (1.3) 7.5 (1.1) 5.7 (1.0) 6.7 (1.0) 11.0 (1.3) 8.1 (0.5) 0.018
Physician-diagnosed
depression, % (s.e.)
5.2 (1.0) 4.2 (0.8) 4.2 (1.0) 3.9 (0.7) 6.5 (1.0) 4.8 (0.4) 0.238
Abbreviations: BMI, body mass index; CES-D, Center for Epidemiologic Studies Depressive scale; IGF-1, insulin-like growth factor 1.
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Table 3. Odds ratio (95% conﬁdence interval) for the cross-sectional association between serum IGF-1 and depression symptoms: the English
Longitudinal Study of Ageing, 2008




1 2 3 4 5
(2–11) (12–14) (15–16) (17–20) (21–65)
Women (analytical sample)
Adjustments
Age (3311) 1 (ref) 0.76 (0.58, 0.97) 0.69 (0.50, 0.93) 0.68 (0.52, 0.90) 0.91 (0.68, 1.22) 0.027 0.009
Age, anthropometric
measuresb (3181)
1 0.79 (0.61, 1.02) 0.74 (0.54, 1.01) 0.72 (0.54, 0.95) 0.96 (0.71, 1.30) 0.061 0.037
Age, co-morbiditiesc (3308) 1 0.75 (0.58, 0.96) 0.68 (0.50, 0.92) 0.69 (0.52, 0.91) 0.89 (0.66, 1.19) 0.031 0.012
Age, psychosocial factorsd
(3162)
1 0.81 (0.62, 1.06) 0.79 (0.57, 1.09) 0.73 (0.55, 0.98) 0.96 (0.70, 1.30) 0.494 0.026
Age, behavioural factorse
(2920)
1 0.77 (0.58, 1.02) 0.76 (0.55, 1.06) 0.76 (0.56, 1.02) 0.91 (0.66, 1.25) 0.08 0.078
Multiply adjusted (2691) 1 0.86 (0.63, 1.16) 0.9 (0.63, 1.29) 0.85 (0.62, 1.29) 1 (0.71, 1.41) 0.756 0.199
Men (analytical sample)
Adjustments
Age (2706) 1 (ref) 0.75 (0.49, 1.16) 0.56 (0.33, 0.95) 0.66 (0.43, 1.02) 1.12 (0.74, 1.69) 0.008 0.004
Age, anthropometric
measuresb (2627)
1 0.85 (0.54, 1.34) 0.62 (0.35, 1.09) 0.79 (0.50, 1.25) 1.26 (0.81, 1.96) 0.037 0.011
Age, co-morbiditiesc (2696) 1 0.76 (0.49, 1.18) 0.58 (0.34, 0.98) 0.64 (0.41, 0.99) 1.11 (0.73, 1.68) 0.009 0.003
Age, psychosocial factorsd
(2592)
1 0.85 (0.54, 1.34) 0.61 (0.35, 1.06) 0.75 (0.47, 1.19) 1.3 (0.90, 2.16) 0.015 0.045
Age, behavioural factorse
(2377)
1 0.68 (0.40, 1.16) 0.57 (0.31, 1.06) 0.71 (0.43, 1.18) 1.32 (0.83, 2.12) o0.001 0.052
Multiply adjusted (2277) 1 0.84 (0.47, 1.50) 0.63 (0.32, 1.24) 0.84 (0.48, 1.47) 1.54 (0.90, 2.64) 0.006 0.153
Abbreviations: BMI, body mass index; IGF-1, insulin-like growth factor 1. aIGF-1 units are nmol l− 1. bBMI, height. cCancer, diabetes, cardiovascular disease. dOwn
wealth quintile per beneﬁt unit (unit is a couple or single person along with their dependent children), education level. eAlcohol consumption, smoking,
physical activity.
Table 4. Odds ratio (95% conﬁdence interval) for the longitudinal association between serum IGF-1 in 2008 and new depression symptoms in 2012:
the English Longitudinal Study of Ageing




1 2 3 4 5
(2–11) (12–14) (15–16) (17–20) (21–65)
Women (analytical sample)
Adjustments
Age (2343) 1 (ref ) 0.88 (0.60, 1.29) 0.77 (0.51, 1.16) 0.84 (0.53, 1.35) 0.95 (0.60, 1.50) 0.647 0.027
Age, anthropometric measuresb
(2276)
1 0.84 (0.57, 1.25) 0.76 (0.50, 1.16) 0.84 (0.52, 1.36) 0.93 (0.58, 1.48) 0.652 0.033
Age, co-morbiditiesc (2342) 1 0.86 (0.58, 1.26) 0.77 (0.51, 1.16) 0.84 (0.53, 1.35) 0.94 (0.60, 1.49) 0.649 0.014
Age, psychosocial factorsd (2243) 1 0.9 (0.60, 1.34) 0.86 (0.56, 1.30) 0.9 (0.55, 1.45) 1.06 (0.66, 1.69) 0.816 0.026
Age, behavioural factorse (2116) 1 0.91 (0.61, 1.35) 0.76 (0.49, 1.17) 0.86 (0.52, 1.40) 0.93 (0.58, 1.51) 0.915 0.029
Multiply adjusted (1969) 1 0.86 (0.56, 1.31) 0.78 (0.50, 1.23) 0.87 (0.52, 1.46) 0.94 (0.56, 1.57) 0.922 0.008
Men (analytical sample)
Adjustments
Age (2076) 1 (ref ) 0.51 (0.28, 0.91) 0.5 (0.27, 0.92) 0.63 (0.35, 1.15) 0.63 (0.35, 1.13) 0.126 0.002
Age, anthropometric measuresb
(2042)
1 0.51 (0.28, 0.94) 0.5 (0.27, 0.93) 0.66 (0.36, 1.20) 0.63 (0.34, 1.14) 0.142 0.002
Age, co-morbiditiesc (2070) 1 0.52 (0.29, 0.94) 0.56 (0.24, 0.85) 0.64 (0.35, 1.16) 0.65 (0.36, 1.16) 0.098 0.002
Age, psychosocial factorsd (2031) 1 0.53 (0.29, 0.97) 0.54 (0.29, 0.99) 0.62 (0.33, 1.17) 0.68 (0.37, 1.24) 0.173 0.001
Age, behavioural factorse (2076) 1 0.52 (0.27, 0.99) 0.49 (0.25, 0.96) 0.67 (0.35, 1.30) 0.58 (0.30, 1.11) 0.165 0.001
Multiply adjusted (1765) 1 0.51 (0.25, 1.02) 0.5 (0.22, 0.95) 0.67 (0.33, 1.33) 0.6 (0.30, 1.19) 0.072 0.003
Abbreviations: BMI, body mass index; IGF-1, insulin-like growth factor 1. aIGF-1 units are nmol l− 1. bBMI, height. cCancer, diabetes, cardiovascular disease. dOwn
wealth quintile per beneﬁt unit (unit is a couple or single person along with their dependent children), education level. eAlcohol consumption, smoking,
physical activity.
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Strengths and limitations
The main strength of this study is that it has a large, nationally
representative sample of people aged 50 years plus in whom
there were high rates of follow-up when two standard measures
of depression were administered. Our study is not of course
without its limitations. The observational nature of our study
indicates that we are not able to make any assertions about cause
and effect. Although suggestions for mechanisms of action have
been posited, it remains possible that IGF-1 levels are a proxy for
other factors that are causally related to depression (residual
confounding). Although our study was very well characterized, we
are not able to control for all possible confounders. Furthermore,
although the CES-D8 is a widely used questionnaire in observa-
tional studies, it does not provide a diagnosis of depression.
Conversely, although self-reported physician-diagnosis of depres-
sion does, in principle, do this, many people with depression do
not seek medical intervention. The use of anti-depressant
medication, which also has some utility in identifying study
members with a depression diagnosis, was not gathered in English
Longitudinal Study of Ageing. It is also the case, however, that
administration of such therapy does not necessarily imply a
diagnosis of depression: anti-depressant medication can be used
in the treatment of, among other conditions, anxiety and chronic
pain disorders. The occurrence of missing data is inevitable in any
large-scale study, and about 10% of participants had missing data
for one or more of the covariates. However, sensitivity analysis
comparing results across the cases with complete information and
those with some missing covariates made little difference to
outcomes, suggesting that major bias is unlikely. Finally, severe
liver and kidney disease may inﬂuence IGF-I levels, but we had no
such data on these morbidities herein.
In conclusion, taken together, in the present study of older
adults, having IGF-1 values at opposite ends of the continuum was
associated with a somewhat increased risk of depression
symptoms and physician-diagnosis of depression. Further studies
are needed to examine whether the observed association is likely
to be causal before meaningful discussions about normalizing
IGF-1 levels with drugs could be useful in the prevention of
depressive symptoms in older people.
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